New drugs are not enough-drug repositioning in oncology: An update

被引：64

作者：

Armando, Romina Gabriela ^{[1
]}

Gomez, Diego Luis Mengual ^{[1
]}

Gomez, Daniel Eduardo ^{[1
]}

机构：

[1] Natl Univ Quilmes, Sci & Technol Dept, Lab Mol Oncol, Roque Saenz Pena 352,B1876, Bernal, Argentina

来源：

INTERNATIONAL JOURNAL OF ONCOLOGY | 2020年 / 56卷 / 03期

关键词：

drug; repositioning; repurposing; oncology; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HIV PROTEASE INHIBITORS; CANCER STEM-CELLS; PHOSPHODIESTERASE TYPE 5; HUMAN PROSTATE-CANCER; PHASE-II TRIAL; OVEREXPRESSING TISSUE INHIBITOR; MYELOID-LEUKEMIA MECHANISMS; CALCIUM-CHANNEL ANTAGONISTS; ENDOTHELIAL GROWTH-FACTOR;

D O I：

10.3892/ijo.2020.4966

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Drug repositioning refers to the concept of discovering novel clinical benefits of drugs that are already known for use treating other diseases. The advantages of this are that several important drug characteristics are already established (including efficacy, pharmacokinetics, pharmacodynamics and toxicity), making the process of research for a putative drug quicker and less costly. Drug repositioning in oncology has received extensive focus. The present review summarizes the most prominent examples of drug repositioning for the treatment of cancer, taking into consideration their primary use, proposed anticancer mechanisms and current development status.

引用

页码：651 / 684

页数：34

共 50 条

[1] Drug Repositioning in Oncology
Serafin, Marissa B.
Bottega, Angelita
da Rosa, Tacieli F.
Machado, Catrine S.
Foletto, Vitoria S.
Coelho, Silvana S.
da Mota, Augusto D.
Horner, Rosmari
AMERICAN JOURNAL OF THERAPEUTICS, 2021, 28 (01) : E111 - E117
[2] Drug development, drug repositioning in oncology
Ozunal, Z. G.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S105 - S105
[3] The Future of Drug Repositioning: Old Drugs, New Opportunities
Doan, Trinh L.
Pollastri, Michael
Walters, Michael A.
Georg, Gunda I.
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 46, 2011, 46 : 385 - 401
[4] Drug repositioning: identifying and developing new uses for existing drugs
Ted T. Ashburn
Karl B. Thor
Nature Reviews Drug Discovery, 2004, 3 : 673 - 683
[5] Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs
Shim, Joong Sup
Liu, Jun O.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2014, 10 (07): : 654 - 663
[6] Drug repositioning: Identifying and developing new uses for existing drugs
Ashburn, TT
Thor, KB
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) : 673 - 683
[7] New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil
Cruz-Burgos, Marian
Losada-Garcia, Alberto
Cruz-Hernandez, Carlos D.
Cortes-Ramirez, Sergio A.
Camacho-Arroyo, Ignacio
Gonzalez-Covarrubias, Vanessa
Morales-Pacheco, Miguel
Trujillo-Bornios, Samantha I.
Rodriguez-Dorantes, Mauricio
FRONTIERS IN ONCOLOGY, 2021, 11
[8] Drug Repositioning for Ovarian Cancer Treatment: An Update
Cavalluzzi, Maria Maddalena
Viale, Maurizio
Rotondo, Natalie Paola
Ferraro, Valeria
Lentini, Giovanni
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2024, 24 (08) : 637 - 647
[9] Drug repositioning: Re-investigating existing drugs for new therapeutic indications
Padhy, B. M.
Gupta, Y. K.
JOURNAL OF POSTGRADUATE MEDICINE, 2011, 57 (02) : 153 - 160
[10] Repositioning Old Drugs for New Uses
Genet. Eng. Biotechnol. News, 9 (1 and 32-33):

← 1 2 3 4 5 →